Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Erlotinib,ERL2023-001,2023,USA,MDV,350,68,45,55,26.5,62,78,5,15,30,40,15,55,25,15,5,20,35,30,18,8,4,10,6,12,38,45,Cisplatin + Gemcitabine,Carboplatin + Paclitaxel,Gemcitabine,Capecitabine,2,1,1,35,55,65,20,45,35,60,2
Erlotinib,ERL2022-002,2022,Canada,Claim Database,420,72,48,52,27.1,58,75,6,18,28,38,16,52,28,14,6,22,33,32,20,9,5,11,7,14,40,48,Cisplatin + Pemetrexed,Carboplatin + Gemcitabine,Pemetrexed,Vinorelbine,3,2,1,38,58,68,22,43,35,62,3
Erlotinib,ERL2024-003,2024,UK,MDV,280,65,42,58,25.8,65,80,4,12,32,42,14,58,22,16,4,18,37,28,16,7,3,9,5,10,35,42,Carboplatin + Pemetrexed,Cisplatin + Docetaxel,Docetaxel,Vinblastine,1,0,0,32,52,62,18,47,35,58,2.5
Erlotinib,ERL2023-004,2023,Germany,Claim Database,480,70,46,54,26.8,60,77,5.5,16,29,39,16,54,26,15,5,21,34,31,19,8.5,4.5,10.5,6.5,13,39,46,Cisplatin + Vinorelbine,Carboplatin + Docetaxel,Vinorelbine,Etoposide,2.5,1.5,0.5,36,56,66,21,44,35,61,2.7
